Minor Intron Splicing from Basic Science to Disease.

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Pre-mRNA splicing, essential for gene expression, is performed by major (U2) and minor (U12) spliceosomes in eukaryotes.
• Minor introns (mi-INTs) constitute less than 0.4% of human introns and require a specialized spliceosome (U11, U12, U4atac, U5, U6atac snRNPs).
• Historically considered inefficient, mi-INTs are now recognized for their regulatory roles in alternative splicing and impact on host gene expression.

Purpose of the Study:

• To review the regulatory mechanisms of minor intron splicing.
• To explore the link between minor splicing deregulation and tissue-specific pathologies.
• To highlight the potential for novel therapeutic strategies targeting minor splicing.

Main Methods:

• Literature review of recent studies on minor intron splicing.
• Analysis of the role of minor spliceosomes in gene expression and disease.
• Synthesis of current understanding of tissue-specific regulation of mi-INTs.

Main Results:

• Minor intron splicing is not necessarily inefficient but plays a significant regulatory role in alternative splicing.
• Deregulation of minor splicing is associated with specific tissue-specific diseases.
• Minor intron-containing genes show altered expression patterns in disease states.

Conclusions:

• Minor intron splicing is a critical regulatory pathway with implications for tissue-specific disease pathogenesis.
• Further research into tissue-specific regulation of mi-INTs is needed for therapeutic advancements.
• Understanding minor splicing offers potential for developing novel therapies for associated diseases.